WO 2004/041318

21

CLAIMS

- Method for providing a shaped biodegradable elastomeric structure comprising forming homopolymers and/or copolymers of 1,3-trimethylene carbonate (TMC) into a desired shape and irradiating said desired shape with actinic radiation in an inert atmosphere for crosslinking.
- 2. Method according to claim 1, wherein the homopolymer and/or copolymer of 1,3-trimethylene carbonate (TMC) is/are characterized by a number average molecular weight (\overline{M}_n) greater than 10,000, preferably between 10,000 to 300,000, and more preferably between 50,000 to 200,000.
- 3. Method according to claim 1 or claim 2, wherein the copolymer of 1,3-trimethylene carbonate (TMC) is chosen from the group consisting of 1,3-trimethylene carbonate (TMC) (co)polymers with lactones (cyclic esters), cyclic carbonates, cyclic ethers, cyclic anhydrides, and cyclic depsipeptides (morpholine 2,5-dione derivatives).
- Method according to any of the claims 1-3, wherein the copolymer of 1,3-trimethylene carbonate (TMC) is chosen from the group consisting of a statistical copolymer, a
 random copolymer, an alternating copolymer, a block polymer, a diblock copolymer, a triblock copolymer, a multiblock copolymer, a star-shaped block copolymer, and a graft block copolymer.
- 5. Method according to any of the claims 1-4, wherein the copolymer of 1,3-trimethylene carbonate (TMC) is chosen from the group consisting of 1,3-trimethylene carbonate (TMC)

WO 2004/041318 PCT/EP2003/012425

22

(co)polymers with polyethylene oxide (PEO), polyethylene glycol (PEG) and ε -caprolactone (CL).

- 6. Method according to any of the claims 1-5, wherein the copolymer of 1,3-trimethylene carbonate (TMC) is chosen from the group consisting of 1,3-trimethylene carbonate (TMC) (co)polymers with δ -valerolacton, 1,5-dioxepane-2-one, and ε -caprolactone.
- 7. Method according to any of the claims 1-6, wherein the copolymer of 1,3-trimethylene carbonate (TMC) is poly(1,3,-trimethylene carbonate-co-&-caprolactone) (poly(TMC-CL)).

, 35°4,

- 8. Method according to any of the claims 1-7, wherein the actinic radiation is chosen from the group consisting of gamma radiation, high-energy UV radiation and electron radiation, preferably gamma radiation.
- 9. Method according to any of the claims 1-8, wherein the actinic radiation is gamma radiation and the irradiation dosage is 5-100 kGy, preferably 10-45 kGy.
- 10. Method according to any of the claims 1-9, 25 wherein the inert atmosphere is obtained by means of a reduced pressure of less than 10⁴ Pa.
- 11. Method according to any of the claims 1-10, wherein the inert atmosphere is obtained by means of an inert 30 gas, preferably nitrogen.
 - 12. Method according to any of the claims 1-11, characterized by a creep rate of the provided shaped

WO 2004/041318 PCT/EP2003/012425

23

biodegradable elastomeric structure of less than 10% of the yield stress.

- 13. Method according to any of the claims 1-12,
 5 characterized by a degree of swelling of the provided shaped biodegradable elastomeric structure of less than 400% in chloroform.
- 14. Method according to any of the claims 1-13, 10 characterized by a gel fraction of the provided shaped biodegradable elastomeric structure of more than 10% by weight.
- 15. Method according to any of the claims 1-14,
 15 comprising sterilization of the provided shaped biodegradable elastomeric structure, preferably in an autoclave.
 - 16. Shaped biodegradable elastomeric structure obtainable by a method according to any of the claims 1-15.
 - 17. Use of a shaped biodegradable elastomeric structure according to claim 16 in or as an implant and/or a matrix and/or a support device.
- 25 18. Medical implant and/or matrix and/or support device comprising a shaped biodegradable elastomeric structure according to claim 16.

20